fentanyl has been researched along with Musculoskeletal Pain in 7 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Musculoskeletal Pain: Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.
Excerpt | Relevance | Reference |
---|---|---|
" We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)." | 9.20 | Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015) |
" We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the treatment of BTP in opioid-tolerant patients with chronic musculoskeletal pain with neuropathic component in terms of relief of pain intensity and assessed whether hypothetical pain relief impacts on quality of life (QoL)." | 5.20 | Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. ( Camba-Rodríguez, A; Cánovas-Martínez, L; Carceller-Ruiz, JJ; De la Iglesia-López, A; Díaz-Parada, P; Domínguez-Suárez, E; Freire-Vila, E; Iglesias, BG; Illodo-Miramontes, G; López-Ulloa, B, 2015) |
"7%) reduced benzodiazepines dosage when prescribing potent opioids." | 1.56 | Strong opioids and non-cancer chronic pain in Catalonia. An analysis of the family physicians prescription patterns. ( Adriyanov, B; Álvarez Carrera, MA; Dürsteler, C; Perelló Bratescu, A; Riera Nadal, N; Sisó-Almirall, A, 2020) |
"While acute musculoskeletal pain is a frequent complaint, its management is often neglected." | 1.43 | A nurse-initiated pain protocol in the ED improves pain treatment in patients with acute musculoskeletal pain. ( Berben, SA; Doggen, CJ; Gaakeer, MI; IJzerman, MJ; Pierik, JG; van Eenennaam, FL; van Vugt, AB, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Perelló Bratescu, A | 1 |
Adriyanov, B | 1 |
Dürsteler, C | 1 |
Sisó-Almirall, A | 1 |
Álvarez Carrera, MA | 1 |
Riera Nadal, N | 1 |
Benoist, GE | 1 |
van Oort, IM | 1 |
Burger, DM | 1 |
Koch, BCP | 1 |
Mehra, N | 1 |
van Erp, NP | 1 |
Graudins, A | 1 |
Meek, R | 1 |
Egerton-Warburton, D | 1 |
Seith, R | 1 |
Furness, T | 1 |
Chapman, R | 1 |
Cánovas-Martínez, L | 1 |
Carceller-Ruiz, JJ | 1 |
Díaz-Parada, P | 1 |
Illodo-Miramontes, G | 1 |
Freire-Vila, E | 1 |
De la Iglesia-López, A | 1 |
Iglesias, BG | 1 |
López-Ulloa, B | 1 |
Domínguez-Suárez, E | 1 |
Camba-Rodríguez, A | 1 |
Pierik, JG | 1 |
Berben, SA | 1 |
IJzerman, MJ | 1 |
Gaakeer, MI | 1 |
van Eenennaam, FL | 1 |
van Vugt, AB | 1 |
Doggen, CJ | 1 |
Chew, KS | 1 |
Shaharudin, AH | 1 |
Chen, YK | 1 |
Lei, J | 1 |
Jin, L | 1 |
Tan, YX | 1 |
You, HJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparison of Sub-dissociative Dose Intranasal Ketamine to Intranasal Fentanyl for Treatment of Moderate to Severe Pain in Pediatric Patients Presenting to the Emergency Department: a Prospective, Randomized, Double-blind Study[NCT02388321] | Phase 4 | 22 participants (Actual) | Interventional | 2015-05-01 | Terminated (stopped due to Patients meeting inclusion criteria was low, and PI went to another institution.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The patient were asked at 30 minutes post administration of analgesia if they experienced any side effects like nausea, vomiting, headache etc. (NCT02388321)
Timeframe: 30 minutes
Intervention | Participants (Count of Participants) |
---|---|
Ketamine | 0 |
Fentanyl | 0 |
An 11 point Likert Visual Analog Scale with 0 being no pain, 5 being moderate pain and 10 being very severe pain was verbally administered to the patient at 30 minutes post administration of analgesia. (NCT02388321)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) |
---|---|
Ketamine | 3.36 |
Fentanyl | 2.09 |
3 trials available for fentanyl and Musculoskeletal Pain
4 other studies available for fentanyl and Musculoskeletal Pain
Article | Year |
---|---|
Strong opioids and non-cancer chronic pain in Catalonia. An analysis of the family physicians prescription patterns.
Topics: Analgesics, Opioid; Benzodiazepines; Chronic Pain; Female; Fentanyl; Health Care Surveys; Humans; La | 2020 |
The Combination of Enzalutamide and Opioids: A Painful Pitfall?
Topics: Analgesics, Opioid; Androgen Antagonists; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cytochr | 2019 |
A nurse-initiated pain protocol in the ED improves pain treatment in patients with acute musculoskeletal pain.
Topics: Acetaminophen; Adult; Analgesics; Diclofenac; Emergency Service, Hospital; Female; Fentanyl; Follow- | 2016 |
Dynamic variations of c-Fos expression in the spinal cord exposed to intramuscular hypertonic saline-induced muscle nociception.
Topics: Analgesics, Opioid; Animals; Fentanyl; Functional Laterality; Gene Expression; Genes, fos; Immunohis | 2013 |